Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/tirzepatide/texas/midlothian
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Midlothian, TX

Verified Tirzepatide providers in Midlothian, TX. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
24
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Texas
25 of 25 shown

Find a Tirzepatide provider in Texas.

Every entry is checked against the NPI registry and the Texas medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Texas city · /tirzepatide/texas/{city}
Cedar Hill
32.58°N
23 →
Waxahachie
32.40°N
27 →
Mansfield
32.57°N
30 →
DeSoto
32.60°N
25 →
Duncanville
32.65°N
25 →
Grand Prairie
32.69°N
32 →
§ 03Getting Tirzepatide in Midlothian
25 providers · Midlothian, TX

How to get Tirzepatide in Midlothian.

25 GLP-1 prescribers and 7 local resource types are on record for Midlothian, plus 3 nearby towns in the directory.

Prescribers in Midlothian
25 prescribers
25 GLP-1 prescribers in Midlothian, most listed as Family Medicine (14), Internal Medicine (7) and Internal Medicine, Endocrinology, Diabetes & Metabolism (2). Any Texas-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Cedar Hill (23 providers), Waxahachie (27 providers) and Mansfield (30 providers).
Around the prescription in Midlothian
7 listed nearby
6 dietitians, 1 nutritionists, 6 gyms, 6 fitness clubs, 3 trainers, 6 physiotherapists and 4 places to move are on record near Midlothian.
Medicaid (weight loss)
Diabetes only
As of April 2026, Texas Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Texas’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Midlothian

Midlothian, Texas has a population of 35,125 people. The adult obesity rate in Midlothian is an age-adjusted estimate of 34.2%, 1.4 percentage points below the Texas state rate of 35.6%. Diagnosed diabetes reaches 9.1% of adults in Midlothian. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 21.5% of adults in Midlothian.

of Midlothian adults have obesity
34.2%
diagnosed diabetes
9.1%
no regular physical activity
21.5%

Age-adjusted estimates for Midlothian, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossthe tirzepatide dosing schedule
§ 05Support around Tirzepatide in Midlothian
6 dietitians

The prescription is one part. Here is the rest, in Midlothian.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Midlothian, TX, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Rebecca Barajas, RDN, LD
RD
Registered dietitian
2400 N I 35
Call 469-843-4141NPI 1891279170
Ella Bonfiglio, RD,LD,CDE
RD
Registered dietitian
1441 S Midlothian Pkwy Ste 100
Call 469-800-9860NPI 1306277801
Tamra Boteler
RD
Registered dietitian · Pediatric
4440 E Highway 287
Call 972-723-5590NPI 1194075762
Ashley Bubert, RD
RD
Registered dietitian · Renal
1507 Hillview Dr
Call 254-582-5577NPI 1740483544
Meredith Milke, RD, LD
RD
Registered dietitian
925 Winecup Way
Call 972-965-4080NPI 1932035581
Sarah Smith, MS RD,LD
RD
Registered dietitian
422 Salt Cedar Dr
Call 972-697-9445NPI 1679446462

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Laura Donnelly, RD
NUTRITIONIST
Nutritionist · Education
3025 Holland Ln
Call 480-363-3302NPI 1245193051
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Texas

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Weight loss doctors in Texas
Board-certified prescribers verified against the NPI registry.
Weight loss clinics in Texas
Clinics running GLP-1 programs, telehealth & in-person.
Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Tirzepatide in Alabama→Tirzepatide in Alaska→Tirzepatide in Arizona→Tirzepatide in Arkansas→Tirzepatide in California→Tirzepatide in Colorado→Tirzepatide in Connecticut→Tirzepatide in Delaware→Tirzepatide in Florida→Tirzepatide in Georgia→Tirzepatide in Hawaii→Tirzepatide in Idaho→Tirzepatide in Illinois→Tirzepatide in Indiana→Tirzepatide in Iowa→Tirzepatide in Kansas→Tirzepatide in Kentucky→Tirzepatide in Louisiana→Tirzepatide in Maine→Tirzepatide in Maryland→Tirzepatide in Massachusetts→Tirzepatide in Michigan→Tirzepatide in Minnesota→Tirzepatide in Mississippi→Tirzepatide in Missouri→Tirzepatide in Montana→Tirzepatide in Nebraska→Tirzepatide in Nevada→Tirzepatide in New Hampshire→Tirzepatide in New Jersey→Tirzepatide in New Mexico→Tirzepatide in New York→Tirzepatide in North Carolina→Tirzepatide in North Dakota→Tirzepatide in Ohio→Tirzepatide in Oklahoma→Tirzepatide in Oregon→Tirzepatide in Pennsylvania→Tirzepatide in Rhode Island→Tirzepatide in South Carolina→Tirzepatide in South Dakota→Tirzepatide in Tennessee→Tirzepatide in Texas→Tirzepatide in Utah→Tirzepatide in Vermont→Tirzepatide in Virginia→Tirzepatide in Washington→Tirzepatide in West Virginia→Tirzepatide in Wisconsin→Tirzepatide in Wyoming→
Related GLP-1 research
the tirzepatide dosing schedule
Starting dose, step-ups, and the 2.5-to-15 mg ladder.
do oral GLP-1 pills work
Pills and drops vs injections: what the evidence supports.
§ 09Frequently asked: Tirzepatide in Texas

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]